ESTRO 37 Abstract book

Hypofractionated external beam radiotherapy for Prostate cancer: what have we learned in the last 15 years?....................................................................... (Abs. 637) State of the art in treatment of oesophageal cancer............................................................ (Abs. 638) MRI based radiotherapy – What can go wrong and how to QA?............................................. (Abs. 639) Photon dosimetry protocols: what is new?......................................................................... (Abs. 640) Treatment planning: where are we and, where are we going................................................ (Abs. 641) Joint Symposium ESTRO-EORTC: New strategies for a clinical research partnership?.................................. (Abs. 642-644) Symposium Automatic planning – the challenges for success.......................................................... (Abs. 645-648) Advances in normal tissue radiobiology....................................................................... (Abs. 649-651) What is the limit of hypofractionation?........................................................................ (Abs. 652-655) Brain tumors in 2018: are there still unsolved problems?. ............................................. (Abs. 656-658) Advances in MRI simulation (MRI-only treatment planning)............................................ (Abs. 659-661) In vivo dosimetry and online dose verification.............................................................. (Abs. 662-664) Advanced planning. ................................................................................................. (Abs. 665-667) Implications of the ageing population for radiation oncology.......................................... (Abs. 668-671) Salvage prostate radiotherapy................................................................................... (Abs. 672-675) Symposium Radiation induced senescence. .................................................................................. (Abs. 676-678) Immunotherapy. ..................................................................................................... (Abs. 679-682) Debate This house believes that stereotactic radiosurgery will replace whole brain radiotherapy in patients with ten brain metastases......................................................................... (Abs. 683-686) Joint Symposium ESTRO-EFOMP: CBCT in radiotherapy: Improving and sharing best practice..................... (Abs. 687-689) Symposium Dose painting – from bench to bed(?)......................................................................... (Abs. 690-693) Debate Autoplanning, is there still a bright future for RTTs after automation?.............................. (Abs. 694-695) Posters Clinical track: Head and Neck.................................................................................... (Abs. 696-710) Clinical track: CNS................................................................................................... (Abs. 711-729) Clinical track: Haematology....................................................................................... (Abs. 730-737) Clinical track: Breast................................................................................................ (Abs. 738-745) Clinical track: Lung.................................................................................................. (Abs. 746-757) Clinical track: Upper GI (oesophagus, stomach, pancreas, liver)..................................... (Abs. 758-788) Clinical track: Lower GI (colon, rectum, anus). ............................................................ (Abs. 789-801) Clinical track: Gynaecological (endometrium, cervix, vagina, vulva)................................ (Abs. 802-815) Clinical track: Prostate............................................................................................. (Abs. 816-829) Clinical track: Urology-non-prostate........................................................................... (Abs. 831-833) Clinical track: Skin cancer / malignant melanoma......................................................... (Abs. 834-835) Clinical track: Sarcoma............................................................................................. (Abs. 836-838) Clinical track: Paediatric tumours............................................................................... (Abs. 839-843) Clinical track: Palliation............................................................................................ (Abs. 844-849) Clinical track: Elderly............................................................................................... (Abs. 850-857) Clinical track: Health services research / health economics............................................ (Abs. 858-859) Clinical track: Communication Clinical track: Other................................................................................................. (Abs. 860-869) Physics track: Basic dosimetry and phantom and detector development. ......................... (Abs. 870-878) Physics track: Dose measurement and dose calculation................................................. (Abs. 879-894) Physics track: Radiation protection, secondary tumour induction and low dose (incl. imaging).. (Abs. 895-898) Physics track: Treatment plan optimisation: algorithms................................................. (Abs. 899-910) Physics track: Treatment planning: applications........................................................... (Abs. 911-928) Physics track: (Radio)biological modelling................................................................... (Abs. 929-933) Physics track: Intra-fraction motion management......................................................... (Abs. 934-950) Physics track: Inter-fraction motion management (excl. adaptive radiotherapy)................ (Abs. 951-957) Physics track: Adaptive radiotherapy for inter-fraction motion management..................... (Abs. 958-965) Physics track: CT Imaging for treatment preparation. ................................................... (Abs. 966-971) Physics track: (Quantitative) functional and biological imaging....................................... (Abs. 972-985) Physics track: Images and analyses. .......................................................................... (Abs. 986-991) Physics track: Implementation of new technology, techniques, clinical protocols or trials (including QA and audit)......................................................................................... (Abs. 992-1012) Physics track: Professional and educational issues Brachytherapy: Breast. ......................................................................................... (Abs. 1013-1014) Brachytherapy: Gynaecolgy. .................................................................................. (Abs. 1015-1018) Brachytherapy: Head and neck....................................................................................... (Abs. 1019)